273
We describe the exceptional development of AML and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after fludarabine treatment followed by autologous peripheral blood stem-cell transplantation.
 ( adverse event: development ,  a patient with previously diagnosed CLL in minimal residual disease status: Subject, AML: Effect, lung cancer: Effect, fludarabine: Treatment, autologous peripheral blood stem-cell transplantation: Treatment, CLL in minimal residual disease status: Treatment.Disorder, fludarabine: Treatment.Drug, autologous peripheral blood stem-cell: Treatment.Drug, transplantation: Treatment.Route, fludarabine: Combination.Drug, autologous peripheral blood stem-cell: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: development ,  a patient with previously diagnosed CLL in minimal residual disease status: Subject, AML: Effect, lung cancer: Effect, fludarabine: Treatment, autologous peripheral blood stem-cell transplantation: Treatment, CLL in minimal residual disease status: Treatment.Disorder, fludarabine: Treatment.Drug, autologous peripheral blood stem-cell: Treatment.Drug, transplantation: Treatment.Route, fludarabine: Combination.Drug, autologous peripheral blood stem-cell: Combination.Drug) 